Arabic Arabic English English French French German German
dark

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and developing pharmacologically tailored antibodies against clinically important targets has been granted by the USPTO as US Patent No. 11,161,901 B2. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Bioengineered Nanoparticles Show Promise for Fibrinogen Manufacture, says Journal of Pharmaceutical Analysis Study

Next Post

iSpecimen Expands COVID-19 Research with Sequences Specimens to Detect Variants

Related Posts
Total
0
Share